Biogen and Xbrane announce commercialization and license agreement for biosimilar to treat rheumatoid arthritis
Under the terms of the agreement, Biogen will make an upfront payment of US $ 8 million to Xbrane
Under the terms of the agreement, Biogen will make an upfront payment of US $ 8 million to Xbrane
It becomes the first ophthalmology biosimilar to gain FDA approval in the United States
Subscribe To Our Newsletter & Stay Updated